Real-world data from a molecular tumor board demonstrates improved outcomes with a precision N-of-One strategy

Real-world data from a molecular tumor board demonstrates improved outcomes with a precision N-of-One strategy

A molecular tumor board (MTB) is often used as a platform that integrates clinical and molecular parameters for clinical decision making. Here, the authors review the outcome of 715 cancer patients presented at their institution’s MTB, and demonstrate that patients who received a MTB-recommended reg...

Description complète

Enregistré dans:
Détails bibliographiques
Auteurs principaux: Shumei Kato, Ki Hwan Kim, Hyo Jeong Lim, Amelie Boichard, Mina Nikanjam, Elizabeth Weihe, Dennis J. Kuo, Ramez N. Eskander, Aaron Goodman, Natalie Galanina, Paul T. Fanta, Richard B. Schwab, Rebecca Shatsky, Steven C. Plaxe, Andrew Sharabi, Edward Stites, Jacob J. Adashek, Ryosuke Okamura, Suzanna Lee, Scott M. Lippman, Jason K. Sicklick, Razelle Kurzrock
Format: article
Langue:EN
Publié: Nature Portfolio 2020
Sujets:
Science
Q
Accès en ligne:https://doaj.org/article/be2daa0bb1884adbb304041e571d8edf
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!
Description
Résumé:A molecular tumor board (MTB) is often used as a platform that integrates clinical and molecular parameters for clinical decision making. Here, the authors review the outcome of 715 cancer patients presented at their institution’s MTB, and demonstrate that patients who received a MTB-recommended regimen received therapy that was better matched to their alterations and achieved better clinical outcomes.

Documents similaires